A Phase 3 interventional study of HRS9531 and HRS9531 placebo in Atherosclerotic Cardiovascular Disease, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Atherosclerosis with a site in China — 36 open to participants now, 48 under way, 11 of them phase 3. Atherosclerosis · China.
Among the 113 studies in Atherosclerosis with a site in China, this one is the 13th largest by planned enrollment of the 79 interventional ones that give a count, is one of 15 that started in 2026, is one of 18 in phase 3, reaches primary completion later than 47 of the 47 other live ones, and was the 104th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →36 of the 113 studies in Atherosclerosis with a site in China are open now. Recruiting first, the newest first:
Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–60 · Healthy volunteers
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
CSL Behring · Sites in China
Ages 18+
Atom Therapeutics Co., Ltd · Sites in China, United States, Australia
Ages 18–75
Hudson Biotech · Sites in China
Ages 40–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 13 · Phase 3 20 · Phase 4 10
First in 2007; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9,262 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 200 across the 79 interventional studies, 928 across the 34 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Fujian Shengdi Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Atherosclerosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
| NCT07729475Shenzhen Salubris Pharmaceuticals Co., Ltd.A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events | 2026-12-12 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 113 studies in Atherosclerosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS9531
Drug: HRS9531 placebo
HRS9531 Dose 1 , subcutaneous injection
HRS9531 placebo Dose 1, subcutaneous injection
The time from randomization to the first occurrence of the MACE-3 composite endpoint
Time frame: approximately up to 61 months of treatment
Time to the first occurrence of the MACE-4 composite endpoint
Time frame: approximately up to 61 months of treatment
Time to the first occurrence of the extended MACE composite endpoint
Time frame: approximately up to 61 months of treatment
Time to the first occurrence of the composite endpoint of heart failure;
Time frame: approximately up to 61 months of treatment
Time to the first occurrence of the composite endpoint of kidney disease;
Time frame: approximately up to 61 months of treatment
Time to the first occurrence of the composite endpoint of major adverse limb events;
Time frame: approximately up to 61 months of treatment;
Time when each component event of the MACE-3 composite endpoint occurred for the first time
Time frame: approximately up to 61 months of treatment;
Time when all-cause death occurs;
Time frame: approximately up to 61 months of treatment;
Time to the first hospitalization due to heart failure;
Time frame: approximately up to 61 months of treatment;
Time to the first emergency heart failure visit;
Time frame: approximately up to 61 months of treatment;
Time when the first persistent eGFR decreased by ≥50% from baseline;
Time frame: approximately up to 61 months of treatment;
Time when persistent eGFR < 15 mL/min/1.73m2 occurred for the first time;
Time frame: approximately up to 61 months of treatment;
Time to first entering chronic renal replacement therapy (dialysis or kidney transplantation) ;
Time frame: approximately up to 61 months of treatment;
The time when renal death occurs;
Time frame: approximately up to 61 months of treatment;
Time to hospitalization for the first occurrence of acute limb ischemia;
Time frame: approximately up to 61 months of treatment;
Time to hospitalization for the first occurrence of unplanned chronic limb ischemia;
Time frame: approximately up to 61 months of treatment
Incidence and severity of adverse events ;
Time frame: Approximately 61 months
Change from baseline in body weight;
Time frame: From randomization to 104 weeks
Change from baseline in waistline;
Time frame: From randomization to 104 weeks
Change from baseline in glycosylated hemoglobin;
Time frame: From randomization to 104 weeks
Change from baseline in blood lipid parameter;
Time frame: From randomization to 104 weeks
Change from baseline in blood pressure;
Time frame: From randomization to 104 weeks
Change from baseline in glomerular filtration;
Time frame: From randomization to 104 weeks
Change from baseline in Uric Acid;
Time frame: From randomization to 104 weeks
Change from baseline in hsCRP;
Time frame: From randomization to 104 weeks
The time to the first unplanned revascularization event
Time frame: approximately up to 61 months of treatment;
Time when the first persistent eGFR decreased by ≥40% from baseline;
Time frame: approximately up to 61 months of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 59 months is above that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribupatide
Fujian Shengdi Pharmaceutical Co., Ltd. →